SMARCB1 and rhabdoid tumor: Rhabdoid tumors are driven by biallelic SMARCB1 inactivation; this loss disrupts the SWI/SNF chromatin remodeling complex, a natural antagonist of PRC2, leading to aberrant PRC2 activation [95].